Clinical Study and Effectiveness of ZRT®-Matrix-Therapy
Supervised clinical Study with 418 Patients followed for at least one year after ZRT®-Matrix Therapy
For many years the clinical application of cellbiologically orientated Matrix Therapy saw significant results. After DAK Gesundheit (one of the largest public health insurance companies in Germany with more than 14 million members), accepted ZRT®-Matrix-Therapy into their program, an extensive study of it's effectiveness was conducted.
A detailed study with 418 patients was carried out on behalf of the insurance company DAK-Gesundheit. The aim of this study was to evaluate ZRT®-Matrix-Therapy in the context of an integrated contract with the Klausenbach Rehabilitation Centre in Nordrach (Black Forest).
Health insurer conducted a stuy to assess effectiveness of ZRT®-Matrix therapy
The rehabilitation treatment was performed by specially trained and ZRT®-certified therapists, following specific medical orthopaedic interventions.
The 418 Included in this study were patients with chronic pain for whom all previous therapies had failed
The patients in the study presented with back pain, neck pain, shoulder pain and tendon disorders. Almost all patients had previously received pharmaceutical therapy and surgery. All other forms of physical therapy must have been unsuccessful, in order for the patients to qualify for this study.
Long term follow up at one year showed stable results
The patients were clinically observed one year after treatment with ZRT® cell biological regulation therapy. The treatment was standardised to six sessions per patient. The treatment was well received and without adverse effects. No patient refused the treatment or discontinued with the therapy on the basis of adverse reactions or pain.
Long term benefits of ZRT®-Matrix Therapy
The majority of patients still showed a significant improvement in mobility and significant pain reduction six months to one year after treatment.
The majority of the patients were able to discontinue their pain medication following ZRT®-Matrix-Therapy
Medication (specifically painkillers), were significantly reduced in the treated groups. The average pain, meaured on a scale of 1-10, was reduced from an average of 5.91 for female patients to 2.85 after the treatment. Male participants showed similar effects (reduction from 5.85 to 3.02 after five treatment sessions)
Working disability (number of working days lost due to the condition) was significantly reduced in the study group
Working disability times were also significantly reduced in the treatment group.
The vast majority of patients described the treatment as pleasant. Patients also estimated their condition themselves as having improved.
